Mytelase

Mytelase Uses, Dosage, Side Effects, Food Interaction and all others data.

Mytelase is a cholinesterase inhibitor. It is used in the management of myasthenia gravis.

Mytelase, similar to pyridostigmine and neostigmine, is used for the treatment of muscle weakness and fatigue in people with myasthenia gravis. It is postulated to exert its therapeutic effect by enhancing cholinergic function through the inhibition of the acetylcholine hydrolysis by acetylcholinesterase. Increased levels of acetylcholine has peripheral effects, as acetylcholine is also used in the brain, where it tends to cause excitatory actions. The glands that receive impulses from the parasympathetic part of the autonomic nervous system are also stimulated in the same way. This is why an increase in acetylcholine causes a decreased heart rate and increased production of saliva. Mytelase is used less commonly than neostigmine or pyridostigmine but may be preferred in patients hypersensitive to the bromide ion. Mytelase produces fewer muscarinic side effects than neostigmine, but more than pyridostigmine.

Mytelase
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Mytelase
Availability	Discontinued
Generic	Ambenonium
Ambenonium Other Names	Ambenonium, Ambenonum
Related Drugs	pyridostigmine, neostigmine, Mestinon, Soliris, Vyvgart, Ultomiris
Type	Tablet
Formula	C₂₈H₄₂Cl₂N₄O₂
Weight	Average: 537.565 Monoisotopic: 536.268482022
Groups	Approved
Therapeutic Class
Manufacturer
Available Country	United States
Last Updated:	September 19, 2023 at 7:00 am

Uses

Mytelase is a cholinesterase inhibitor that targets both muscarinic and nicotinic receptors indicated for the treatment of myasthenia gravis.

Mytelase is used to treat muscle weakness due to muscle disease (myasthenia gravis).

How Mytelase works

Mytelase exerts its actions against myasthenia gravis by competitive, reversible inhibition of acetylcholinesterase. The disease myasthenia gravis occurs when the body inappropriately produces antibodies against acetylcholine receptors, and thus inhibits proper acetylcholine signal transmission (when acetylcholine binds to acetylcholine receptors of striated muscle fibers, it stimulates those fibers to contract). Mytelase reversibly binds acetylcholinesterase at the anionic site, which results in the blockage of the site of acetycholine binding, thereby inhibiting acetylcholine hydrolysis and enhancing cholinergic function through the accumulation of acetycholine at cholinergic synpases. Elevated acetylcholine levels lead to facilitates transmission of impulses across the myoneural junction.

Toxicity

LD₅₀=150±44 mg/kg (orally in mice). Symptoms of overdose include muscle twitching, weakness and paralysis of voluntary muscles including the tongue, shoulders, neck and arms, blood pressure increase (with or without a slowing of heart rate), a sensation of internal trembling, severe anxiety, and panic. Death may occur rapidly if untreated.